Back to search
FDAFDA · Food and drugs·Recall number D-0469-2024

Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13

Published May 1, 2024 · Recall initiated: April 9, 2024

Summary

FDA records drug Class III recall D-0469-2024, published May 1, 2024 and initiated April 9, 2024. Recalling firm: Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.; Status: Ongoing; Reported quantity: N/A; Lot: Lot # APS00423A, Exp 07/31/2025; APS00222A, Exp 11/30/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products

What to do

Voluntary: Firm initiated · Letter

Get an email if ABILIFY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ABILIFY
Manufacturer
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Distributor
USA nationwide.
Lot
Lot # APS00423A, Exp 07/31/2025; APS00222A, Exp 11/30/2024
Risk classification
Class III
Area (FDA)
drug
Country
Japan

Related recalls

Questions about this recall

Was Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13 recalled?

Yes. FDA published recall D-0469-2024 on May 1, 2024. Reported hazard: Cross Contamination with Other Products

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ABILIFY.